



Enabling Equitable Access to Patients

Leveraging THE POWER OF ONE
Ensuring Affordable Access to Lifesaving Biosimilars,
Worldwide

Biocon Biologics is a unique, fully integrated leading global biosimilars player that is driven by an unwavering purpose to enable equitable access to high-quality, lifesaving biosimilars for patients globally.

Biocon Biologics is an end-to-end biosimilars enterprise with established capabilities in the development, manufacturing and commercialization of high-quality biosimilars. The company is leveraging cutting-edge science, advanced R&D skills, innovative tech platforms, global-scale manufacturing capabilities and internationally benchmarked quality and regulatory systems to address the global need for essential medicines to treat chronic diseases. Eight of its biosimilars, including insulins and antibodies, have been commercialized and are benefiting over 5.5 million patients annually in more than 100 countries.

As an industry pioneer, Biocon Biologics is among the first wave of companies to commercialize multiple biosimilars in the U.S., Europe and several other advanced and emerging market countries. These include Trastuzumab, Bevacizumab and Pegfilgrastim for cancer; Insulin Glargine, Insulin Aspart and recombinant human Insulin for diabetes, and Adalimumab and Etanercept for autoimmune diseases.

BIOSIMILARS FRONTRUNNER

A frontrunner in the global biosimilars industry, Biocon Biologics has invested over USD 1 billion in building dedicated 'lab to market' capabilities for biosimilars. This has led to the creation of two state-of-the-art R&D facilities in India and three large-scale, globally compliant manufacturing facilities in India and Malaysia. The company has also invested in best-in-class quality processes and technology to meet the most stringent quality standards and successfully gain regulatory approvals in several jurisdictions, including U.S., EU, Australia, Canada and Japan. Biocon Biologics has achieved many global 'firsts,' including the industry's first approval of an interchangeable biosimilar for Insulin Glargine in the U.S. It is also the first globally to receive approvals for biosimilar Trastuzumab and biosimilar Pegfilgrastim from the U.S. Food and Drug Administration (FDA).

The company has been able to establish brand equity with patients, prescribers, payors and regulators through an impeccable track record of quality, safety, and reliability.

BIOCON BIOLOGICS: QUICK FACTS

Bengaluru, India Employees, 5,500+

FY2022 FINANCIAL HIGHLIGHTS :

USD 462 mn (Revenue)

SIZE OF BIOSIMILARS PIPELINE: 20

COMMERCIALIZED BIOSIMILARS: 8

Pegfilgrastim	Aspart
Trastuzumab	rh-Insulin
Bevacizumab	Adalimumab*
Glargine U100	Etanercept*

Commercial reach: 100+ countries

Patients served globally: 5.5+ mn / year

Strong scientific talent and state-of-the-art R&D infrastructure

R&D sites: 2 (Bengaluru, Chennai)

Drug substance, drug product & devices manufacturing capabilities for insulins, mAbs

Manufacturing sites: 3
(2 in Bengaluru, India; 1 in Johor, Malaysia)

cGMP approvals received: 25+

Bio-Manufacturing Capacity:
Among Top 15 globally

**In-licensed products*



THE 'POWER OF ONE'

To strengthen its leadership position in the global biosimilars industry, Biocon Biologics has acquired the global biosimilars business of its long-term partner Viartis for over USD 3 billion in cash and stock. This is a historic milestone in the company's value creation journey and brings it closer to patients, customers, and payors in several advanced and emerging market countries.

By combining the complementary capabilities and strengths of two long-term partners, it is leveraging THE POWER OF ONE with an aim to reduce healthcare inequities and transform healthcare, worldwide.



COMPREHENSIVE PORTFOLIO

Biocon Biologics is well-positioned for future growth as the addressable market for its comprehensive pipeline of 20 biosimilars for diabetes, cancer, autoimmune diseases, ophthalmic conditions and bone health is estimated to grow from USD 25 billion in FY23 to USD 78 billion in FY28.

Oncology	Immunology	Diabetes	Ophthalmology	Bone Health
Pegfilgrastim	Adalimumab ¹	Glargine U100	Aflibercept ²	Denosumab
Trastuzumab	Ustekinumab	Aspart		
Bevacizumab	Etanercept ¹	Rh-Insulin		
Pertuzumab		Glargine U300		

Seven undisclosed assets

¹ In-licensed products

² BBL has acquired Viartis' global rights to partnered asset



EXPANDING INTO ADJACENCIES

Besides a robust biosimilars franchise, Biocon Biologics also has a strategic alliance with Serum Institute Life Sciences for vaccines (subject to regulatory approvals and closure of the transaction) to address inequitable access to lifesaving vaccines worldwide.



STRONG ESG FOCUS

Environmental, Social and Governance (ESG) is at the core of Biocon Biologics' business purpose and responsibility. The company's philosophy of unconditional equity aims to ensure the well-being of patients, people, partners, customers, shareholders, communities and the ecosystem at large. By serving patients, protecting the environment and promoting business integrity, the company is taking 'sustainable action' every day, reinforcing its commitment to building an equitable and viable future.

Note: The information in this Fact Sheet is given as of the date below, and Biocon Biologics does not undertake any obligation to update any information in the document.

Last Updated: May 04, 2023

Leadership Team

Kiran Mazumdar-Shaw
Executive Chairperson

Shreehas Tambe
CEO & Managing Director

Chinappa M B
Chief Financial Officer

Matthew Erick
Chief Commercial Officer -
Advanced Markets

Susheel Umesh
Chief Commercial Officer -
Emerging Markets

Anuj Goel
Chief Scientific Officer

Sandeep Nilkanth Athalye
Chief Medical Officer

Michael Cutter
Chief Quality Officer

Ganesh Reddy
Global Head of Manufacturing

Kiran Kumar Gandhirajan
Site Head, Malaysia

Seema Ahuja
Global Head - Corporate Brand &
Head of Communications – Emerging
Markets

Stephanie Wasco
Head of Communications – Advanced
Markets

Paul Vazhayil Thomas
Global Head - Portfolio & Program
Management

Stephen Manzano
General Counsel – Advanced Markets

Akhilesh Nand
General Counsel – Emerging Markets

Naveen Narayanan
Chief Human Resources Officer

Biocon Biologics Limited

Biocon House, Semicon Park, Electronics City,
Phase - II, Hosur Road, Bengaluru, Karnataka
560 100. India. T: **+91 80 6775 6775**.
Email: **Group.Communications@biocon.com**
Website: **www.bioconbiologics.com**

Follow us at :     